Long-term safety studies extending up to 12 months showed no adverse effects, which is rare for a compound with such potent biological activity
Comparative study on anorexigenic effect of glucagon-like peptide-1 receptor agonists in rats
Retatrutide is not approved anywhere, Eli Lilly had not filed an NDA as of mid-2026, and its long-term safety data is still maturing
Song Y, Lei L, Cai X, Wei H, Yu CY (2024) Immunomodulatory peptides for tumor treatment
ANGPTL4 is a catalyst of renal fibrosis in diabetes and disrupts cytokine and chemokine reprogramming by upregulating TGF signaling (Srivastava et al., 2024)
Your doctor should evaluate opportunities to reduce costs and determine if you have any contraindications such as medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2